申请人:Pfizer Inc.
公开号:US20140206670A1
公开(公告)日:2014-07-24
The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.
本发明涉及一种组合物,特别是一种协同作用的组合物,包括α-2-δ配体和双重血清素-去甲肾上腺素再摄取抑制剂(DSNRI)或一种或两种选择性血清素再摄取抑制剂(SSRI)和选择性去甲肾上腺素再摄取抑制剂(SNRI),以及其药学上可接受的盐,制药组合物及其在治疗疼痛,特别是神经病性疼痛中的应用。